- A New Study from UC San Francisco May Offer the First Clear Biological Markers for Frontotemporal Dementia, A CONDITION THAT OFTEN AFFFECTS PEOPLE IN MIDLIFE AND IS DIFFICULT TO DIAGNOSE.
- By analysis spinal fluid from patients with inherited Frontotemporal DementiaUncovered Protein Refracchers Changes Linked to RNA Regulation and Brain Connectivity; Early indicators that could lead to earlier, more action diagnosis.
- These Findings Could Open The Door to Precision Treatments and Expanded Access to Clinical Trials for Those Living With The Disease.
Dementia Typically Affects Older Adults, So When It Appears in Middle Age It Can Be Difcult to Identify.
The Most Common Type In This Age Group is frontotemporal Dementia, which is ophniagnosed as depression, Schizophrenia, or Parkinson’s Disease.
Frontotemporal disorders are caused by Damage to the front and temporal regions of the brain, leading to dementia. The Effects Vary By Type But May Include Changes in Behaviour, Language, and Overall Wellbeing.
Now, Refers AT UC San Francisco Have Uncovered New Insights Into How Frontotemporal Dementia Developops.
The Study, Published in
Refrachers Combase tohe samples to those from 39 of Their Healthy Relatives.
CHANGES IN PROTEIN COMPOSION LINKED TO FRONTOTEMPORAL DEMINIA
Since All Participants With Frontotemporal Dementia Had Genetic Forms of the Disease, The Team Was Able to Study Confirm Cases In Living Individuals.
This was not be positive with non-inherited frontotemporal dementia, as This can only be defined diagnosed postmortem.
The Changes in Protein Composition Suggest That Thuee with Frontotemporal Dementia Experience Disruptions in
The Team Believes before Could Serve As The First Specific Biomarkers for Frontotemporal Dementia That Become detectable as The Disease Begins to manifest in Middle Age.
Do not define Method to diagnose frontotemporal dementia
By identifying frontotemporal dementia at an earlier stage, potentially this Treatments.
First Author Rowan, PHD, Scientist-Practitage and Assistant Professor at The UCSF Memory and Aging Center, Explained The Key Findings To Medical News Today.
“Wezzed brain fluid samples from individuals with inherited form of frontotemporal dementia, a Group of Progressive Dementias That Primarily Affect Individuals in Midlife (40s, 50s, and 60s),” Skate Explained.
“Studying inherited Forms of (Frontotemporal Dementia) Allows US To Know The Underlying Brain Pathology in Living Patients With High Confidenze, Making It A Powerful Model for Deteting Biological Changes, Even Before Symptoms Begin. By Measuring Concentrations of Thousands of Thousand Proteins in brain fluid, we identified biological changes related to rna processing, synaptic health, and immune responsibles that were Associated with Greater Severity of Disease. “
– Rowan jumps, pHD
“Importantly, We Replicated Many of Our Findings in People with Sporadic (Noninherited) Forms of (Frontotemporal Dementia), Showing that the biological changes we unchavered could be reluct to a large percantage of (frontotemporal dementia) patients,” I have add. “
James Giordano, PHD, Mphil, Professor Emeritus in The Departments of Neurology and Biochemistry at Georgetown University Medical Center, Washington, Told MNT that “This is an important study using proteomic analytics techniques to assses putative biomarkers for frontotemporal lobe dementia (ftld).”
“In the Main, this study, using relativly Large Cohort of Patient Samples, Viable Proteomic Biomarkers for By Genetic Deletion Mechanisms-Which Prevent the Expression of Benefit Sublates of Neural and Glial Factors That Can Remave Certain Certain Forms of Cellular End-Product Debris-And Addition Process, WHICH CONTAINS Such As Tau, which are contributory to mechanisms of neurodegeneration in ftld, and other neurologic demonstrations.
– James Giordano, PHD
“One Constraint of This Study was The Use of A particular Proteomic Scaning Tool,” Giordano Added. This is scholary it “May introduces subd” selection preference “or bias in protemic biomarker, identification.”
However, “It is nonetheless important in that it establishs the Opportunity to use other proteomic scanning tools, as well as prompting development of new biomarker assessments that may be Even More Useful in This Type of Assessment and Potentially Predictive Analysis,” EXPLAINED.
“The Benefit of Studies Such as This is that Early Identification of Proteomic Biomarkers Can Lead To New Trageectors of Drug Development That Can Divert Pathogenic Mechanisms of Aberant, Protein Production and Aggregation, Which Thereby Might Prevent or Mitigate Progress of Ftld, and Other neurodegenerative conditions. “
– James Giordano, PHD
Not Approved Therapies for Frontotemporal Dementia
JOINED EXPLAED THAT “UNLike Alzheimer’s Disease, which now you have biomarkers and emerging treatments, frontotemporal dementia still you have not approved therapies.”
“IN SPORADIC (NONGENETIC) (Frontotemporal Dementia) Cases, We Also Lack Reliable Ways to Determine Given Patient’s Brain Pathology During Life.”
“Our Study Moves The Field Closer to Molecular Tests That Could Detest Disease Earlier, Monitor ITS PROGRESSION, AND GUIDE CUSTOZED TREATMENTS BASED ON UNDERLYING BIOLOOL.
– Rowan jumps, pHD
